Stock Financial Ratios, Dividends, Split History

CNO / CNO Financial Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)3,276.84
Enterprise Value ($M)3,520.62
Book Value ($M)4,617.20
Book Value / Share27.59
Price / Book0.71
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 170,025,000
Common Shares Outstanding 166,876,131
Common Stock Shares Outstanding 166,857,931
Weighted Average Number Of Diluted Shares Outstanding 172,144,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.01
Return on Equity (ROE)0.04
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues Excluding Realized Gains Losses4,194,200,000.00
Revenue Relatedto Transitionand Support Services Agreements0.00
Revenues Related To Certain Non Strategic Investments And Earnings Attributable To Non Controlling Interests52,700,000.00
Net Income175.60
Earnings Per Share Basic1.03
Earnings Per Share Diluted1.02
Cash Flow Statement (mra) ($M)
Cash From Operations613.10
Cash from Investing-239.60
Cash from Financing-239.60
Identifiers and Descriptors
Central Index Key (CIK)1224608
Related CUSIPS
012621E10 12621E903 12621E953 12621E107

Split History

Stock splits are used by CNO Financial Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

7 Insurers Poised to Outperform in Q2 on Many Tailwinds

2018-07-12 zacks
The Finance sector is set to kick off its earnings season this week with major banks reporting quarterly results. Improving rate environment and tax cuts should continue to drive the sector’s performance. Per the Earnings Outlook, earnings for the sector are expected to increase 18.5% on 3.6% higher revenues. Insurers, an important component of the Finance sector, are shortly going to release their financial numbers. (1-0)

I Recently Purchased This 10% Yielding BDC

2018-06-28 seekingalpha
TCPC is likely under-priced for the reasons discussed in this article, trading under book value, RSI of 38, and offering a well-supported 10% dividend yield. (45-0)

Unum (UNM) Raises Dividend by 13%, Okays $750M Share Buyback

2018-05-27 zacks
In a bid to enhance shareholder value, the board of directors of Unum Group (UNM - Free Report) recently hiked its quarterly dividend by 13% and approved a new $750-million share buyback program. The new dividend payout amounts to 24 cents per share compared with 23 cents paid earlier. The annualized dividend of $1.04 per share yields 2.7%, based on the closing price of $38.54 as of May 24. Shareholders are expected to be awarded with the meatier dividend during the third quarter of 2018. (55-0)

MetLife's Approves Share Buyback, Boosts Shareholders' Value

2018-05-23 zacks
MetLife, Inc.’s (MET - Free Report) board of directors has approved a new buyback authorization of common shares worth $1.5 billion. The recent announcement is in tandem with the company’s goal of returning $5 billion in capital to its shareholders in 2018. Last year, the company had announced a $2 billion repurchase under which it has bought back nearly $1.63 billion worth shares. Shares worth around $370 million still remains under its 2017 authorization. (52-0)

Chubb (CB) Enhances Shareholder Value With 3% Dividend Raise

2018-05-18 zacks
In a bid to share more profits with its shareholders, the board of directors of Chubb Limited (CB - Free Report) recently announced a 3% hike in quarterly dividend to 73 cents per share. Shareholders of record as of Jun 22 will have the meatier dividend in their pockets on Jul 13, 2018. The annualized dividend of $2.92 per share translates into a yield of 2.2% based on the closing price of $134.45 on May 17, 2018. (50-0)

CUSIP: 12621E103